ReviewJournal of Crohn's & colitis2025
Novel outcomes in inflammatory bowel disease.
Review in Journal of Crohn's & colitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and network meta-analysis of integrated traditional Chinese and conventional medicine for ulcerative colitis.Frontiers in pharmacology · 2026Pooled it
- Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial.Journal of Crohn's & colitis · 2026Trial
- Visual theranostic oral nanozymes for IBD from principles to preclinical design.Bioactive materials · 2026Review
- Optimising clinical trial design choices in inflammatory bowel disease.BMJ open gastroenterology · 2026Review
- Compound Kushen Injection Alleviates Experimental Colitis in Mice by Regulating Macrophage Polarization through TLR4/NF-κB Signaling.Chinese journal of integrative medicine · 2026Article
- Metabolite-Related Evidence Linking Metabolic Measures to Patient-Reported Outcomes in Inflammatory Bowel Disease: A Critical Narrative Review.Metabolites · 2026Review
- Food choices and beliefs in adults with inflammatory bowel disease in Sweden.BMC gastroenterology · 2026Article
- Berberine AlleviatesInternational journal of molecular sciences · 2026Article
- Rethinking clinical response criteria in trials of chronic enteropathy in dogs: what change is truly meaningful?Journal of veterinary internal medicine · 2026Article
- Current approaches to disease severity and therapy effectiveness assessment in patients with inflammatory bowel disease.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Learning curve in intestinal ultrasound: advancing from basic skills to advanced competencies-insights from the IUS IG-IBD Master program.Journal of Crohn's & colitis · 2026Article
- Oral delivery of engineeredMaterials today. Bio · 2026Article
- Nanomaterial-Based Strategies Targeting IL-1 Signalling in Inflammatory Bowel Disease: Therapeutic Applications and Mechanistic Insights.Journal of inflammation research · 2026Review
- Assessment of Bowel Urgency in Ulcerative Colitis: Current Measures and Future Directions.Gastro hep advances · 2026Review
- Research Progress on the Mechanism of Ginsenoside Rg1 in Inflammatory Bowel Disease.Journal of immunology research · 2026Review
- Mechanisms and therapeutic prospects of DNA methylation-mucosal innate immunity crosstalk in inflammatory bowel disease.Frontiers in immunology · 2026Review
- Subcellular Localization Dictates Therapeutic Function: Spatially Targeted Delivery of Amuc_1100 by EngineeredNutrients · 2025Article
- Exploring the Potential Value of Lactylation and Macrophage Polarization-Related Genes as Biomarkers for TNF-α Inhibitor Response in Inflammatory Bowel Disease.Journal of inflammation research · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
Inflammatory bowel diseases (IBD), Crohn's disease (CD), and ulcerative colitis (UC) are lifelong chronic, relapsing, and remitting conditions that culminate in disease progression in many patients. Effective management of CD and UC requires consideration of both short- and long-term treatment outcomes. Historically, short-term outcomes such as clinical and endoscopic remission and symptom relief have been evaluated in clinical trials. With the expansion of treatments targeting underlying disease pathophysiology, there is the opportunity to develop management strategies that improve disease control and patients' lives in both the short and the long term. Researchers have been examining novel outcomes for assessing the efficacy of CD and UC treatments that are important to patients, and also those that go beyond symptomatic improvements or clinical remission. These include new patient-reported outcomes for symptoms, as well as transmural/histological healing and disease clearance that can be more reflective of deeper remission states and disease modification. This review analyses published clinical studies involving patients with UC and CD treated with biologics or small molecule therapies. It highlights novel IBD endpoints employed in published clinical trials and discusses their likely value for assessing disease activity and disease modification, and as predictors of reduced risk of complications and morbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.